Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment

We isolated a SARS-CoV-2 BA.2 variant from a person with COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing was performed and compared with parental SARS-CoV-2 and multiple variants of concern. We found that neither NM resistance no...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlin, Aaron F., Clark, Alex E., Chaillon, Antoine, Garretson, Aaron F., Bray, William, Porrachi, Magali, Santos, AsherLev T., Smith, Davey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128786/
https://www.ncbi.nlm.nih.gov/pubmed/35611335
http://dx.doi.org/10.21203/rs.3.rs-1662783/v1
Descripción
Sumario:We isolated a SARS-CoV-2 BA.2 variant from a person with COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing was performed and compared with parental SARS-CoV-2 and multiple variants of concern. We found that neither NM resistance nor absence of neutralizing immunity were likely causes of the recrudescence.

Ejemplares similares